Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.

ABSTRACT:

Purpose

Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and two weekly injectable regimens for treatment of type 2 diabetes (T2D).

Methods

Participants with T2D in the UK reported preferences and valued four health state vignettes in time trade-off utility interviews. The vignettes had identical descriptions of T2D but differed in treatment process: (1) daily simple oral treatment (tablets without administration requirements), (2) daily oral semaglutide (with administration requirements per product label), (3) weekly dulaglutide injection, (4) weekly semaglutide injection.

Results

SUBMITTER: Matza LS 

PROVIDER: S-EPMC8233232 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature